Johnson & Johnson (NYSE:JNJ) Shares Acquired by Parallel Advisors LLC

Parallel Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 76,195 shares of the company’s stock after acquiring an additional 3,724 shares during the period. Parallel Advisors LLC’s holdings in Johnson & Johnson were worth $12,636,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Lowe Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson by 16.5% in the 1st quarter. Lowe Wealth Advisors LLC now owns 714 shares of the company’s stock valued at $118,000 after acquiring an additional 101 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company’s stock valued at $1,196,596,000 after purchasing an additional 7,185,977 shares during the last quarter. AdvisorNet Financial Inc grew its stake in shares of Johnson & Johnson by 3.3% in the 1st quarter. AdvisorNet Financial Inc now owns 11,479 shares of the company’s stock valued at $1,904,000 after purchasing an additional 362 shares during the last quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO grew its stake in shares of Johnson & Johnson by 1.8% in the 1st quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 38,900 shares of the company’s stock valued at $6,451,000 after purchasing an additional 681 shares during the last quarter. Finally, Nexus Investment Management ULC lifted its holdings in shares of Johnson & Johnson by 9.4% in the 1st quarter. Nexus Investment Management ULC now owns 9,331 shares of the company’s stock valued at $1,547,000 after buying an additional 805 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on JNJ shares. Morgan Stanley lifted their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 16th. Leerink Partners downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Raymond James reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research note on Monday, April 14th. Finally, Barclays cut their price target on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 17th. Eleven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Stock Up 0.7%

Shares of JNJ opened at $153.44 on Friday. The firm’s 50-day simple moving average is $154.43 and its 200 day simple moving average is $153.63. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The firm has a market cap of $369.19 billion, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.39%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.